Nasdaq:AKRO

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025

May 10, 2025 10:00 ET  | Source: Akero Therapeutics Inc. Analysis of EFX results with AI-based digital pathology underscores the…

6 days ago
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHAkero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

January 24, 2025 16:05 ET  | Source: Akero Therapeutics Inc. Investor webcast on Monday, January 27, 2025, at 8:00 a.m.…

4 months ago
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHAkero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

January 24, 2025 16:05 ET  | Source: Akero Therapeutics Inc. Investor webcast on Monday, January 27, 2025, at 8:00 a.m.…

4 months ago
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASHAkero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH

January 24, 2025 16:05 ET  | Source: Akero Therapeutics Inc. Investor webcast on Monday, January 27, 2025, at 8:00 a.m.…

4 months ago
Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceAkero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Akero Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 07, 2025 07:00 ET  | Source: Akero Therapeutics Inc. SOUTH SAN FRANCISCO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) --…

4 months ago